Results 21 to 30 of about 8,814 (196)

Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes

Journal of Diabetes Research, 2018
miR-122, the expression of which is regulated by several transcription factors, such as HNF1A, was recently reported to be associated with type 2 diabetes (T2DM) and hepatocellular carcinoma. HNF1A variants can cause diabetes and might be involved in the
Xiuting Huang, Siqian Gong, Yumin Ma, Xiaoling Cai, Lingli Zhou, Yingying Luo, Meng Li, Wei Liu, Simin Zhang, Xiuying Zhang, Qian Ren, Yu Zhu, Xianghai Zhou, Rui Zhang, Ling Chen, Xueying Gao, Fang Zhang, Yanai Wang, Xueyao Han, Linong Ji   +19 more
doaj   +2 more sources

Rethinking HNF1A-MODY: HNF1A at the crossroads of development and multiorgan metabolic disease. [PDF]

Genes Dev
In this issue of Genes & Development , Unger and colleagues (doi:10.1101/gad.353153.125) combined human pluripotent stem cell-derived in vitro models with targeted in vivo mouse models to reveal multiple developmental defects triggered by HNF1A ...
Warin J, Grapin-Botton A.
europepmc   +3 more sources

HASTER is a transcriptional stabilizer of HNF1A [PDF]

Endocrinology, Diabetes & Metabolism Case Reports, 2021
Abstract The biological purpose and disease relevance of long noncoding RNAs (lncRNAs) is poorly understood. We examined HASTER , a lncRNA antisense to HNF1A .
Beucher, Anthony, Miguel-Escalada, Irene, Balboa, Diego, De Vas, Matías G., Maestro, Miguel Angel, Garcia-Hurtado, Javier, Bernal, Aina, Gonzalez-Franco, Roser, Vargiu, Pierfrancesco, Heyn, Holger, Ravassard, Philippe, Ortega, Sagrario, Ferrer, Jorge   +12 more
openaire   +4 more sources

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

A nationwide assessment of hepatocellular adenoma resection: Indications and pathological discordance

Hepatology Communications, EarlyView., 2022
Abstract Hepatocellular adenomas (HCAs) are benign liver tumors associated with bleeding or malignant transformation. Data on the indication for surgery are scarce. We analyzed indications and outcome of patients operated for HCAs < 50 mm compared to HCAs ≥ 50 mm. Changes in final postoperative diagnosis were assessed.
Martijn P. D. Haring, Arthur K. E. Elfrink, Christiaan A. J. Oudmaijer, Paul C. M. Andel, Alicia Furumaya, Nenke de Jong, Colin J. J. M. Willems, Thijs Huits, Julie M. L. Sijmons, Eric J. T. Belt, Koop Bosscha, Esther C. J. Consten, Mariëlle M. E. Coolsen, Peter van Duijvendijk, Joris I. Erdmann, Paul Gobardhan, Robbert J. de Haas, Tjarda van Heek, Hwai‐Ding Lam, Wouter K. G. Leclercq, Mike S. L. Liem, Hendrik A. Marsman, Gijs A. Patijn, Türkan Terkivatan, Babs M. Zonderhuis, Izaak Quintus Molenaar, Wouter W. te Riele, Jeroen Hagendoorn, Alexander F. M. Schaapherder, Jan N. M. IJzermans, Carlijn I. Buis, Joost M. Klaase, Koert P. de Jong, Vincent E. de Meijer, the Dutch Benign Liver Tumor Group, R. B. Takkenberg, J. Verheij, O. M. van Delden, J. I. Erdmann, B. V. van Rosmalen, A. Furumaya, G. Kazemier, D. Ramsoekh, J. N. M. IJzermans, R. A. de Man, M. D. Doukas, M. G. Thomeer, A. J. Klompenhouwer, A. F. M. Schaapherder, M. E. Tushuizen, M. J. Coenraad, A. S. L. P. Crobach, M. C. Burgmans, S. Feshtali, M. M. E. Coolsen, M. Kramer, J. C. Beckervordersandforth, I. V. Samarska, C. van der Leij, R. Miclea, J. H. W. de Wilt, P. B. van den Boezem, E. T. T. L. Tjwa, I. Munsterman, S. Vos, S. van Koeverden, V. E. de Meijer, F. J. C. Cuperus, R. J. de Haas, E. W. Duiker, M. P. D. Haring   +70 more
wiley   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study. [PDF]

Diabetes Obes Metab
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Audrain E, Bel Lassen P, Bellanné-Chantelot C, Vantyghem MC, Dupuis H, Vidal-Trecan T, Chevalier N, Dubois-Laforgue D, Lamothe S, Vatier C, Villard O, Valéro R, Briet C, Vigouroux C, Ciangura C, Amouyal C.   +15 more
europepmc   +2 more sources

HASTER lncRNA promoter is a cis-acting transcriptional stabilizer of HNF1A [PDF]

, 2022
The biological purpose of long non-coding RNAs (lncRNAs) is poorly understood. Haploinsufficient mutations in HNF1A homeobox A (HNF1A), encoding a homeodomain transcription factor, cause diabetes mellitus.
Vas, Matías G. de, Gonzalez-Franco, Roser, Heyn, Holger, Ravassard, Philppe, Balboa, Diego, Garcia-Hurtado, Javier, De Vas, Matías G, Gonzalez Franco, Roser, Beucher, Anthony, Bernal, Aina, Miguel-Escalada, Irene, Vargiu, Pierfrancesco, De Vas, Matías G., Angel Maestro, Miguel, Miguel Escalada, Irene, De Vas, Matias, Maestro, Miguel Angel, Ferrer, Jorge, Ravassard, Philippe, Ortega, Sagrario   +19 more
core   +1 more source

HNF1a-induced promoter activities of Akr1c12 and 13 in HEK293 cells.

, 2021
HEK293 cells were co-transfected with HNF1a and luciferase reporter construct containing Akr1c12 (-1115 to -1) or Akr1c13 (-1006 to -1) promoter region. All values represent mean ± SEM. (PDF)
Domenico Accili (185429), Jinsook Son (11766939), Yasutaka Miyachi (3178986), Taiyi Kuo (2863205)   +3 more
core   +1 more source

Novel Loss-of-Function Variant in HNF1a Induces β-Cell Dysfunction through Endoplasmic Reticulum Stress

, 2022
Heterozygous variants in the hepatocyte nuclear factor 1a (HNF1a) cause MODY3 (maturity-onset diabetes of the young, type 3). In this study, we found a case of novel HNF1a p.Gln125* (HNF1a-Q125ter) variant clinically.
Yuxian Zhang, Zhao, Qing, Zhang, Yuxian, Li, Xuejun, Huang, Caoxin, Likun Wang, Wang, Likun, Qing Zhao, Xuejun Li, Mingyu Li, Chen, Yinling, Juanjuan Tian, Huang, Bingkun, Jianxin Jia, Jia, Jianxin, Yinling Chen, Li, Mingyu, Caoxin Huang, Tian, Juanjuan, Bingkun Huang   +19 more
core   +1 more source

The First Case of Digenic MODY Diabetes Involving Compound Heterozygosity of Three Variants in the PDX1 and HNF1B Genes [PDF]

Mol Genet Genomic Med
A history of a woman diagnosed with diabetes at 15 led to the discovery of the first digenic MODY with compound heterozygosity of three variants in the PDX1 and HNF1B genes and family cascade screening. This underscores the importance of next‐generation sequencing in the differential diagnosis of diabetes type and extra‐pancreatic abnormalities ...
Płonka‐Stępień M, Szopa M, Zawada M, Malecki M.   +3 more
europepmc   +2 more sources